Literature DB >> 19015224

Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss.

P J Francis1, S C Hamon, J Ott, R G Weleber, M L Klein.   

Abstract

BACKGROUND: Age related macular degeneration (AMD) is a leading cause of blindness. AMD is a complex disorder caused by genetic and environmental factors in which single nucleotide polymorphisms (SNPs) in the genes CFH and LOC387715/HTRA1/ARMS2 have prognostic importance for progression to advanced AMD (with visual loss). CFH may also have a pharmacogenetic role by affecting treatment response to widely used nutritional supplements. This paper examines other AMD susceptibility genes to determine if these genotypes influenced disease progression and treatment response.
METHODS: Three cohorts, totalling 3137 individuals, were genotyped for SNPs in 13 genes previously published to be associated with advanced AMD (other than CFH and LOC387715/ARMS2/HTRA1). Those genes found associated were then evaluated for their involvement in disease progression. Interactions between the genes and with AREDS (Age-Related Eye Disease Study) nutritional supplements were investigated.
RESULTS: Positive independent associations were noted in SNPs in the genes C2 (p = 0.0001, odds ratio (OR) 0.35, 95% confidence interval (CI) 0.2 to 0.6), CFB (p = 0.0001, OR 0.35, 95% CI 0.2 to 0.6), C3 (p = 0.0001, OR 3.91, 95% CI 1.94 to 7.88), APOE (epsilon4, p = 0.01, OR 0.50, 95% CI 0.29 to 0.86) and VEGFA (p = 0.01, OR 2.23, 95% CI 1.06 to 4.68). C2/CFB and C3 were independently related to progression from early/intermediate to advanced AMD with OR 0.32 (95% CI 0.14 to 0.73) and 3.32 (95% CI 1.46 to 7.59), respectively. Gene-gene and pharmacogenetic interactions were not observed. No preferential associations were observed with geographic atrophy or choroidal neovascularisation.
CONCLUSION: This study provides insights into the genetic pathogenesis of AMD. Five genes have now been shown to be independently involved in progression from intermediate disease (before vision loss has occurred) to advanced disease in which blindness is frequent.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19015224     DOI: 10.1136/jmg.2008.062737

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  51 in total

Review 1.  Age-related macular degeneration: genetic and environmental factors of disease.

Authors:  Yuhong Chen; Matthew Bedell; Kang Zhang
Journal:  Mol Interv       Date:  2010-10

2.  Pooled-analysis of the associations between three polymorphisms in the VEGF gene and age-related macular degeneration.

Authors:  Yan Lu; Yuhua Shi; Chunyan Xue; Jie Yin; Zhenping Huang
Journal:  Mol Biol Rep       Date:  2012-02-04       Impact factor: 2.316

Review 3.  Complement pathway biomarkers and age-related macular degeneration.

Authors:  M Gemenetzi; A J Lotery
Journal:  Eye (Lond)       Date:  2015-10-23       Impact factor: 3.775

Review 4.  [Genetic and risk factors for exudative AMD].

Authors:  M Dietzel; A Farwick; H-W Hense
Journal:  Ophthalmologe       Date:  2010-12       Impact factor: 1.059

Review 5.  The molecular genetic basis of age-related macular degeneration: an overview.

Authors:  Saritha Katta; Inderjeet Kaur; Subhabrata Chakrabarti
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

6.  Allelic variants of complement genes associated with dense deposit disease.

Authors:  Maria Asuncion Abrera-Abeleda; Carla Nishimura; Kathy Frees; Michael Jones; Tara Maga; Louis M Katz; Yuzhou Zhang; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 10.121

Review 7.  Genetics of age-related macular degeneration: current concepts, future directions.

Authors:  Margaret M Deangelis; Alexandra C Silveira; Elizabeth A Carr; Ivana K Kim
Journal:  Semin Ophthalmol       Date:  2011-05       Impact factor: 1.975

Review 8.  Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy.

Authors:  S Scott Whitmore; Elliott H Sohn; Kathleen R Chirco; Arlene V Drack; Edwin M Stone; Budd A Tucker; Robert F Mullins
Journal:  Prog Retin Eye Res       Date:  2014-12-05       Impact factor: 21.198

Review 9.  Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications.

Authors:  Claudio Campa; Ciro Costagliola; Carlo Incorvaia; Carl Sheridan; Francesco Semeraro; Katia De Nadai; Adolfo Sebastiani; Francesco Parmeggiani
Journal:  Mediators Inflamm       Date:  2010-08-25       Impact factor: 4.711

10.  Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration.

Authors:  Amy M Fang; Aaron Y Lee; Mukti Kulkarni; Melissa P Osborn; Milam A Brantley
Journal:  Mol Vis       Date:  2009-12-10       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.